All In Biotech

Drug Trial Radar · NCT04972227

Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia

A Double-blinded, Randomized, Placebo-controlled, Multiple-ascending-dose Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia

Last checked: Nov 19, 2026Latest source record: Aug 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Sep 10, 2021

Primary completion

Apr 18, 2022

Study completion Apr 18, 2022

Sponsor

Lead sponsor
Tisento TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the safety and tolerability of CY6463 when administered to participants with stable schizophrenia who are on a stable antipsychotic medication regimen

Conditions

  • Schizophrenia

Interventions

  • CY6463Drug

    oral tablets

  • PlaceboDrug

    oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and TEAEs leading to study drug discontinuationTime frame: 28 (±4) days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Collaborative Neuroscience Network

    Long Beach, California

  • Hassman Research Institute

    Marlton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.